Suggested remit: To appraise the clinical and cost effectiveness of teprotumumab within its marketing authorisation for treating thyroid eye disease.
- Status:
- Deferred
- Process:
- STA Standard
- ID number:
- 6432
- Deferred ID number:
- D1
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Amgen Limited (teprotumumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- British Thyroid Foundation
- The Thyroid Trust
- Professional groups
- Royal College of Ophthalmologists
- Royal College of Physicians
- Society for Endocrinology
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 March 2026 | Deferred. NICE is currently unable to issue a recommendation on the use of teprotumumab for treating thyroid eye disease within the NHS. This is because Amgen has chosen to defer its consultation response to NICE. The evaluation of teprotumumab for treating thyroid eye disease is anticipated to recommence in June 2026 under ID6756. |
| 02 July 2025 - 23 July 2025 | Draft guidance: 1 |
| 15 July 2025 | Committee meeting: 1 |
| 03 April 2025 | Declaration of interests |
| 29 October 2024 | Invitation to participate |
| 18 July 2024 - 15 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6432 |
| 18 July 2024 | In progress. Scoping commenced. |
| 10 April 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual